References
- AntmanEMAnbeDTArmstrongPWACC/AHA guidelines for the management of patients with ST-elevation myocardial infarctionJ Am Coll Cardiol20044467171915358045
- AntmanEMMorrowDAMcCabeCHExTRACT-TIMI 25 investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarctionN Engl J Med200635414778816537665
- ArmstrongPWChangWCWallentinLASSENT-3 and ASSENT-3 PLUS investigators. Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS dataCMAJ20061741421616682709
- BauerKANew anticoagulants: Anti IIa vs Anti Xa – Is one better?J Thromb Thrombolysis200621677216475045
- BauersachsRMFondaparinux: An update on new study resultsEur J Clin Invest200535Suppl 1273215701145
- CoussementPKBassandJPConvensCA synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE studyEur Heart J20012217162411511121
- FreedmanMDPharmacodynamics, clinical indications, and adverse effects of heparinJ Clin Pharmacol199232584961322434
- GurfinkelEFareedJAntmanERationale for the management of coronary syndromes with low-molecular-weight heparinsAm J Cardiol19988215L18L
- MehtaSRStegPGGrangerCBRandomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary interventionCirculation200511113909715781750
- TurpieAGBauerKAErikssonBIFondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studiesArch Intern Med200216218334012196081
- YusufSMehtaSRChrolaviciusSThe Fifth Organization to Access Strategies in Acute Ischemic Syndromes InvestigatorsComparison of fondaparinux and enoxaparin in acute coronary syndromesN Engl J Med200635414647616537663
- YusufSMehtaSRChrolaviciusSEffects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction. The OASIS-6 randomized trialJAMA29515193016537725